TP53 and cancer: On the contrary, we speculate that, when p53 is deleted, cancer cells rely on different mechanisms in order to acquire resistance to anticancer drugs and, thus, the synergistic p53-dependent effect exerted by HDACi in combination with anticancer drugs is lost.